97 related articles for article (PubMed ID: 14501260)
1. Intrinsic activity estimation of cannabinoid CB1 receptor ligands in a drug discrimination paradigm.
De Vry J; Jentzsch KR
Behav Pharmacol; 2003 Sep; 14(5-6):471-6. PubMed ID: 14501260
[TBL] [Abstract][Full Text] [Related]
2. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
McMahon LR
Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the discriminative stimulus properties of delta 9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys.
Gold LH; Balster RL; Barrett RL; Britt DT; Martin BR
J Pharmacol Exp Ther; 1992 Aug; 262(2):479-86. PubMed ID: 1323651
[TBL] [Abstract][Full Text] [Related]
4. Characterization of two cloned human CB1 cannabinoid receptor isoforms.
Rinaldi-Carmona M; Calandra B; Shire D; Bouaboula M; Oustric D; Barth F; Casellas P; Ferrara P; Le Fur G
J Pharmacol Exp Ther; 1996 Aug; 278(2):871-8. PubMed ID: 8768742
[TBL] [Abstract][Full Text] [Related]
5. Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors.
Govaerts SJ; Hermans E; Lambert DM
Eur J Pharm Sci; 2004 Nov; 23(3):233-43. PubMed ID: 15489124
[TBL] [Abstract][Full Text] [Related]
6. Central mediation of the cannabinoid cue: activity of a selective CB1 antagonist, SR 141716A.
Pério A; Rinaldi-Carmona M; Maruani J; Barth F; Le Fur G; Soubrié P
Behav Pharmacol; 1996 Jan; 7(1):65-71. PubMed ID: 11224395
[TBL] [Abstract][Full Text] [Related]
7. Discriminative stimulus functions of AM-1346, a CB1R selective anandamide analog in rats trained with Delta9-THC or (R)-methanandamide (AM-356).
Järbe TU; Lamb RJ; Liu Q; Makriyannis A
Psychopharmacology (Berl); 2006 Oct; 188(3):315-23. PubMed ID: 16953384
[TBL] [Abstract][Full Text] [Related]
8. Acute delta9-tetrahydrocannabinol exposure facilitates quinpirole-induced hyperlocomotion.
Gorriti MA; Ferrer B; del Arco I; Bermúdez-Silva FJ; de Diego Y; Fernandez-Espejo E; Navarro M; Rodríguez de Fonseca F
Pharmacol Biochem Behav; 2005 May; 81(1):71-7. PubMed ID: 15894066
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation.
McCoy KL; Matveyeva M; Carlisle SJ; Cabral GA
J Pharmacol Exp Ther; 1999 Jun; 289(3):1620-5. PubMed ID: 10336560
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships defining the ACD-tricyclic cannabinoids: cannabinoid receptor binding and analgesic activity.
Melvin LS; Milne GM; Johnson MR; Wilken GH; Howlett AC
Drug Des Discov; 1995 Nov; 13(2):155-66. PubMed ID: 8872458
[TBL] [Abstract][Full Text] [Related]
11. Discriminative stimulus effects of the structurally novel cannabinoid CB1/CB2 receptor partial agonist BAY 59-3074 in the rat.
De Vry J; Jentzsch KR
Eur J Pharmacol; 2004 Nov; 505(1-3):127-33. PubMed ID: 15556145
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoids alter recognition memory in rats.
Kosiorek P; Hryniewicz A; Bialuk I; Zawadzka A; Winnicka MM
Pol J Pharmacol; 2003; 55(5):903-10. PubMed ID: 14704485
[TBL] [Abstract][Full Text] [Related]
13. Increasing the selectivity of the discriminative stimulus effects of delta 9-tetrahydrocannabinol: complete substitution with methanandamide.
Alici T; Appel JB
Pharmacol Biochem Behav; 2004 Nov; 79(3):431-7. PubMed ID: 15582014
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs.
Melvin LS; Milne GM; Johnson MR; Subramaniam B; Wilken GH; Howlett AC
Mol Pharmacol; 1993 Nov; 44(5):1008-15. PubMed ID: 8246904
[TBL] [Abstract][Full Text] [Related]
15. Ras/ERK signalling in cannabinoid tolerance: from behaviour to cellular aspects.
Rubino T; Forlani G; Viganò D; Zippel R; Parolaro D
J Neurochem; 2005 May; 93(4):984-91. PubMed ID: 15857401
[TBL] [Abstract][Full Text] [Related]
16. Behavioral effects of the novel cannabinoid full agonist AM 411.
McLaughlin PJ; Lu D; Winston KM; Thakur G; Swezey LA; Makriyannis A; Salamone JD
Pharmacol Biochem Behav; 2005 May; 81(1):78-88. PubMed ID: 15894067
[TBL] [Abstract][Full Text] [Related]
17. The dopamine receptor antagonist SCH 23390 attenuates feeding induced by Delta9-tetrahydrocannabinol.
Verty AN; McGregor IS; Mallet PE
Brain Res; 2004 Sep; 1020(1-2):188-95. PubMed ID: 15312802
[TBL] [Abstract][Full Text] [Related]
18. A novel component of cannabis extract potentiates excitatory synaptic transmission in rat olfactory cortex in vitro.
Whalley BJ; Wilkinson JD; Williamson EM; Constanti A
Neurosci Lett; 2004 Jul; 365(1):58-63. PubMed ID: 15234473
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid agonist, CP 55,940, prevents capsaicin-induced sensitization of spinal cord dorsal horn neurons.
Johanek LM; Simone DA
J Neurophysiol; 2005 Feb; 93(2):989-97. PubMed ID: 15385593
[TBL] [Abstract][Full Text] [Related]
20. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
Sain NM; Liang A; Kane SA; Urban MO
Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
